Leukemia
Conditions
Keywords
adult acute myeloid leukemia in remission, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(8;21)(q22;q22), adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with t(16;16)(p13;q22), childhood acute myeloid leukemia in remission
Brief summary
RATIONALE: Giving chemotherapy and colony-stimulating factors, such as G-CSF, may increase the number of stem cells in the blood. The stem cells are collected from the patient's blood and stored. Chemotherapy or radiation therapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation therapy. PURPOSE: This clinical trial is studying how well an autologous stem cell transplant works in treating patients with acute myeloid leukemia.
Detailed description
OBJECTIVES: * To assess whether sufficient peripheral blood stem cells (PBSC) can be collected from patients with acute myeloid leukemia (AML) using cyclophosphamide, etoposide, and granulocyte-colony stimulating factor (G-CSF) mobilization. * To assess the rate of myeloid, platelet, and erythroid recovery following autologous PBSC transplant. * To assess the disease-free survival rate of patients with AML receiving PBSC auto grafts. OUTLINE: * Chemotherapy and filgrastim (G-CSF) priming for PBSC collection: Patients receive cyclophosphamide IV on day 0; etoposide IV over 3 hours on days 0 and 1; and oral dexamethasone twice daily on days 0 and 1. Patients also receive G-CSF subcutaneously (SC) beginning on day 3 and continuing until apheresis is complete. After blood counts recover, apheresis is performed in 4-6 daily planned collections until the minimum CD34+ cell dose of \> 2.5 x 10\^6 cells/kg is achieved. If the minimum CD34+ cell dose is not achieved after 6 apheresis collections, patients undergo bone marrow examination including a bone marrow biopsy and aspiration, at the termination of the PBSC collection to confirm remission. If remission is confirmed, and if peripheral counts and marrow cellularity are sufficient, the patient remains off G-CSF for 7 days and receives sargramostim (GM-CSF) for 5 days to increase the marrow cellularity, after which a bone marrow harvest is performed. * Bone marrow harvest without prior PBSC collection: Children will undergo primed bone marrow harvest comprising GM-CSF IV or SC for 5 days prior to harvest to increase cellularity and then marrow is harvested. Marrow and blood specimens are also obtained with the initial bone marrow evaluation and at the time of harvest if a cytogenetic abnormality was previously described. Other patients who are unable to undergo PBSC collection may proceed with a bone harvest at the discretion of the protocol chairperson. * Cytoreductive regimen: * Patients over 2 years old: Patients undergo total body irradiation (TBI) twice daily on days -7 to -4 (total of 8 fractions), cyclophosphamide IV over 2 hours on days -3 and -2, followed by a 1-day rest period on day -1. * Patients under 2 years old and patients who cannot undergo TBI: Patients receive busulfan IV or orally every 6 hours on days -7 to -4, cyclophosphamide IV over 2 hours on days -3 to -2, followed by a 1-day rest period on day -1. * Stem cell transplantation: All patients undergo autologous PBSC and/or bone marrow infusion on day 0. Patients also receive G-CSF IV or SC beginning on day 1 and continuing until blood counts recover. After completion of study treatment, patients are followed periodically for 5 years.
Interventions
BIOLOGICALsargramostim
Given subcutaneously (SC) 10 μg/kg/day from day +3 until apheresis is completed
DRUGbusulfan
4 mg/kg po in 4 divided doses (.8 mg/kg/dose orally every 6 hours) on days -7 through -4.
DRUGcyclophosphamide
4 gm/m\^2 x 1 (day 0) and 60 mg/kg intravenous (IV) over 2 hours on days -3 and -2.
DRUGdexamethasone
20 mg/m\^2 x 4 doses every 12 hours given intravenously (IV) push before cytoxan on day 0 and then every 12 hours
DRUGetoposide
300 mg/m\^2/day x 2 days (day 0-1) over 3 hours intravenously (IV)
PROCEDUREbone marrow transplantation
Day 0 infusion of bone marrow cells
PROCEDUREhematopoietic stem cell transplantation
Stem cell infusion (\>48 hours after the last dose of cyclophosphamide)
PROCEDUREperipheral blood stem cell transplantation
Day 0 infusion of peripheral blood stem cells
RADIATIONtotal-body irradiation
165 cGy/dose given twice a day on days -7 through -4.
Sponsors
Masonic Cancer Center, University of Minnesota
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 70 Years
Healthy volunteers
No
Inclusion criteria
Children under the age of two are eligible for this protocol, but will not receive total body irradiation. Instead, children under the age of two will receive Busulfan/Cyclophosphamide (Bu/Cy) conditioning as the preparative regimen in order to obviate deleterious effects of radiation at this age. Patients who cannot receive total body irradiation (TBI) (for example those with prior radiation therapy) will also receive the Bu/CY conditioning. * Acute myeloid leukemia (AML) * All children and adults less than the age of 70 with AML who have achieved a first or second bone marrow remission are eligible for this protocol. Patients must undergo peripheral blood stem cell collection or marrow harvest while in remission and must not be expected to have better outcomes with allogeneic transplantation. * Patients with cytogenetic abnormalities suggesting an improved prognosis \[t(8:21), t(15;17) and inv(16)\] will be eligible for transplantation in first remission. * Allogeneic transplant with an HLA-identical sibling will be recommended for patients \<55 years. If the patient refuses allogeneic transplant, they may still be eligible for this protocol.
Exclusion criteria
* Patients can also be deemed not eligible for transplant because of specific organ toxicity. Specifically, patients with pre-existing compromise to the heart, lungs, kidney, CNS or liver may be excluded: * Eastern Cooperative Oncology Group (ECOG) Performance status: 0 or 1 * Heart - The patient must be free of symptoms of uncontrolled cardiac disease, and must not have compromised cardiac function detected by ECHO or by gated cardiac blood flow scan (MUGA) LVEF \>45%). * Kidney - The patient must have a corrected creatinine clearance \>50% of normal. * Liver - The total serum bilirubin \< 2.5 mg/dL; ALT \<2 x upper limit of normal. * Lung - Patients must have no significant obstructive airways disease or resting hypoxemia (PO2 \<80), and must have acceptable diffusion capacity (DLCO \> 50% of predicted). * Central Nervous System (CNS): Patients must be free of active or ongoing ischemic or degenerative CNS disease and no active or resistant CNS leukemia.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Engraftment | 30 Days Post Transplant | Percentage of Participants with Engraftment measured by myeloid, platelet, and erythroid recovery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Disease Response | 2 years Post Transplant | Disease evaluation will be completed approximately 100 days after stem cell infusion and every 6 months, 1 year, and until 2 years after infusion. |
| Treatment Failure | 2 years Post Transplant | Percentage of participants experiencing treatment failure. |
| Percent of Patients With Various Late Effects | 2 years Post Transplant | Description: (e.g., thyroid function abnormalities - T4, TSH, gonadal abnormalities, cataracts, pulmonary dysfunctions, growth and development abnormalities, and second malignant neoplasms) |
| Disease-free Survival | 2 years Post Transplant | Disease-free survival 2 years Post Transplant |
| Percentage of Patients With Adequate Cells Collected | Pre-Transplant | The proportion of primed patients with adequate number of cells collected will be calculated. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Bone Marrow Transplant (2-70 Years Old) Patients over the age of two will receive a cytoreductive regimen of total-body irradiation and cyclophosphamide (TBI/CY) as well as sargramostim, dexamethasone, etoposide, transplantation (bone marrow transplantation/hematopoietic stem cell transplantation/peripheral blood stem cell transplantation).
sargramostim: Given subcutaneously (SC) 10 μg/kg/day from day +3 until apheresis is completed
cyclophosphamide: 4 gm/m\^2 x 1 (day 0) and 60 mg/kg intravenous (IV) over 2 hours on days -3 and -2.
dexamethasone: 20 mg/m\^2 x 4 doses every 12 hours given intravenously (IV) push before cytoxan on day 0 and then every 12 hours
etoposide: 300 mg/m\^2/day x 2 days (day 0-1) over 3 hours intravenously (IV)
bone marrow transplantation: Day 0 infusion of bone marrow cells
peripheral blood stem cell transplantation: Day 0 infusion of peripheral blood stem cells
total-body irradiation: 165 cGy/dose given twice a day on days -7 through -4. | 12 |
| Bone Marrow Transplant (Less and 2 Years Old) Patients under the age of two, and patients who cannot receive total body irradiation (TBI), will receive a cytoreductive regimen of Busulfan and cyclophosphamide (BU/CY) as per the Johns Hopkins University Hospital regimen as well as sargramostim, dexamethasone, etoposide, transplantation (bone marrow transplantation/hematopoietic stem cell transplantation/peripheral blood stem cell transplantation).
sargramostim: Given subcutaneously (SC) 10 μg/kg/day from day +3 until apheresis is completed
busulfan: 4 mg/kg po in 4 divided doses (.8 mg/kg/dose orally every 6 hours) on days -7 through -4.
cyclophosphamide: 4 gm/m\^2 x 1 (day 0) and 60 mg/kg intravenous (IV) over 2 hours on days -3 and -2.
dexamethasone: 20 mg/m\^2 x 4 doses every 12 hours given intravenously (IV) push before cytoxan on day 0 and then every 12 hours
etoposide: 300 mg/m\^2/day x 2 days (day 0-1) over 3 hours intravenously (IV)
hematopoietic stem cell transplantation: Stem cell infusion (\>48 hours after the last dose of cyclophosphamide) | 0 |
| Total | 12 |
Baseline characteristics
| Characteristic | Bone Marrow Transplant (2-70 Years Old) | Bone Marrow Transplant (Less and 2 Years Old) | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 12 Participants | 0 Participants | 12 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 8 Participants | 0 Participants | 8 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 4 Participants | 0 Participants | 4 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 11 Participants | 0 Participants | 11 Participants |
| Region of Enrollment United States | 12 participants | — | 12 participants |
| Sex: Female, Male Female | 6 Participants | 0 Participants | 6 Participants |
| Sex: Female, Male Male | 6 Participants | 0 Participants | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 12 |
| other Total, other adverse events | 0 / 12 |
| serious Total, serious adverse events | 1 / 12 |
Outcome results
Primary
Percentage of Participants With Engraftment
Percentage of Participants with Engraftment measured by myeloid, platelet, and erythroid recovery
Time frame: 30 Days Post Transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Bone Marrow Transplant (2-70 Years Old) | Percentage of Participants With Engraftment | 100 Participants of participants |
Secondary
Disease-free Survival
Disease-free survival 2 years Post Transplant
Time frame: 2 years Post Transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Bone Marrow Transplant (2-70 Years Old) | Disease-free Survival | 73 Percentage of participants with DFS |
Secondary
Percentage of Participants With Disease Response
Disease evaluation will be completed approximately 100 days after stem cell infusion and every 6 months, 1 year, and until 2 years after infusion.
Time frame: 2 years Post Transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Bone Marrow Transplant (2-70 Years Old) | Percentage of Participants With Disease Response | 83 Percentage of participants |
Secondary
Percentage of Patients With Adequate Cells Collected
The proportion of primed patients with adequate number of cells collected will be calculated.
Time frame: Pre-Transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Bone Marrow Transplant (2-70 Years Old) | Percentage of Patients With Adequate Cells Collected | 75 Percentage of participants |
Secondary
Percent of Patients With Various Late Effects
Description: (e.g., thyroid function abnormalities - T4, TSH, gonadal abnormalities, cataracts, pulmonary dysfunctions, growth and development abnormalities, and second malignant neoplasms)
Time frame: 2 years Post Transplant
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Bone Marrow Transplant (2-70 Years Old) | Percent of Patients With Various Late Effects | 0 Participants |
Secondary
Treatment Failure
Percentage of participants experiencing treatment failure.
Time frame: 2 years Post Transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Bone Marrow Transplant (2-70 Years Old) | Treatment Failure | 25 Percentage of participants |